Company intelligence / Profile preview

Canary Cure Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Canary Cure’s lead candidate, CCT‑217, is a first-in-class dual siRNA therapy targeting CB1R and ZFP423 for obesity. Preclinical results show significant weight loss with preservation of lean body mass and potential for single or twice-yearly dosing. The company plans to submit an IND in Q3 2025 and begin Phase 1 clinical trials in 2026.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: RNA interference (RNAi)siRNA therapeuticsmicroRNA diagnostics
Industry: Biotech

Drug pipeline

10 assets

CCT-317

Preclinical

9 more assets in the full pipeline.

Request access →

Partnerships

Not publicly disclosed as of May/June 2025

Beyond the preview

Go deeper on Canary Cure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canary Cure Therapeutics.

Explore the full profile